Methylglyoxal Modified Proteins anticorps

N° du produit ABIN2192148

Cet anticorps anti-Methylglyoxal Modified Proteins Monoclonal Souris (Clone MGO-1) (ABIN2192148) détecte spécifiquement Methylglyoxal Modified Proteins dans IHC (p), WB et IA. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour Methylglyoxal Modified Proteins anticorps (ABIN2192148)

Antigène: Methylglyoxal Modified Proteins

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Inconjugué

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB), Immunoassay (IA)

Clone: MGO-1

Détail du produit

Réactivité croisée (Details): Cross reactivity: Multispecies : Yes

Stérilité: 0.2 μm filtered

Isotype: IgG1

Information d'application

Indications d'application: For immunohistochemistry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting.

Restrictions: For Research Use only

Stockage

Buffer: PBS, containing 0.1 % bovine serum albumin and 0.02 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.

Détail du antigène

Antigène: Methylglyoxal Modified Proteins

Sujet: The monoclonal antibody MGO-1recognizes human MGO modified proteins. Methylglyoxal (MGO) is an endogenous product of glucose metabolism. Increased production and accumulation of methylglyoxal (MGO), as well as increased modification of proteins by glycoxidation, are hallmarks of aging and diabetes. MGO was shown to modify proteins and to contribute to the accumulation of damaged proteins that can be toxic to cells. A number of studies have shown that MGO levels are significantly elevated in patients with Type 2 Diabetes and correlates well with fasting plasma glucose and hemoglobin A1c (HbA1c) levels. Moreover, increased formation of the MGO is implicated in renal dysfunction and is known to be involved in the development of DN (diabetic nephropathy). Immunogen MGO-modified KLH